Comparison of Cardiovascular Events Among Users of Different Classes of Antihypertension Medications
Open Access
- 5 February 2020
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 3 (2) , e1921618
Abstract
Hypertension is the most prevalent risk factor for mortality and disability-adjusted life-years1 worldwide. Cardiovascular disease remains the leading cause of death globally, accounting for 17.7 million deaths in 2015, which represented 31% of all deaths worldwide.2 Hypertension is an important factor in cardiovascular disease.3 In 2010, it was estimated that one-third of the world’s adult population had hypertension.4 The introduction of the American College of Cardiology and the American Heart Association hypertension guidelines in 2017 resulted in higher estimates of the number of people with hypertension.5,6 Knowledge of optimal first-line antihypertension medications for the prevention of cardiovascular events and mortality will be important for clinical decision-making. Moreover, the identification of treatments that are most effective for controlling hypertension and subsequent cardiovascular events and mortality and that have the least harmful effects is imperative to guide clinicians and decrease cardiovascular disease burdens worldwide.Keywords
This publication has 30 references indexed in Scilit:
- Ranking treatments in frequentist network meta-analysis works without resampling methodsBMC Medical Research Methodology, 2015
- Graphical Tools for Network Meta-Analysis in STATAPLOS ONE, 2013
- Meta-analyses: how to read a funnel plotBMJ, 2013
- Hypertension and Cardiovascular Disease: Contributions of the Framingham Heart StudyGlobal Heart, 2013
- Consistency and inconsistency in network meta‐analysis: concepts and models for multi‐arm studiesResearch Synthesis Methods, 2012
- Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studiesBMJ, 2009
- Health Outcomes Associated With Various Antihypertensive Therapies Used as First-Line AgentsJAMA, 2003
- Blood pressure and cardiovascular disease in the Asia Pacific regionJournal Of Hypertension, 2003
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Blood pressure, stroke, and coronary heart disease *1Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution biasThe Lancet, 1990